Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/11578
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPeng, H.-
dc.contributor.authorCallison, D.-
dc.contributor.authorLi, P.-
dc.contributor.authorBurrell, C.-
dc.date.issued1999-
dc.identifier.citationHuman Gene Therapy, 1999; 10(3):449-462-
dc.identifier.issn1043-0342-
dc.identifier.issn1557-7422-
dc.identifier.urihttp://hdl.handle.net/2440/11578-
dc.description.abstractCoexpression of different effector molecules from a single vector (a dual-function vector) may provide enhanced efficacy. Thus far most of the reported anti-HIV dual-function vectors express different effector RNAs as a chimeric molecule. In our study involving retroviral vectors coexpressing a U5 ribozyme and either an anti-tat or anti-rev antisense RNA, chimeric vectors exhibit poor potency in several important functional aspects, including inhibition of HIV replication, protection against cytopathic effects, and suppression of target gene function. Surprisingly, such a poor efficacy of chimeric vector function was not associated with a lower level of effector RNA expression. These results indicate that expression of two effector RNAs as a chimeric molecule can lead to interference, reducing their global biological effects. More importantly, we have demonstrated that such interference can be avoided by coexpressing these effector RNAs as separate molecules through a new dual-function vector, called a dual-effector cassette (Dec) vector, developed in this study. We also define some of the design alterations that might affect the efficacy of the Dec vector and demonstrate that forward-designed Dec vectors are more efficacious than reverse-designed Dec vectors, which express a lower level of effector RNA owing to the instability of the 5' effector cassettes in the provirus. We believe that the principle of Dec vector design may also be applicable for the coexpression of other therapeutic RNA effectors in many gene therapy applications.-
dc.description.statementofresponsibilityHairong Peng, Deborah Callison, Peng Li, Christopher J. Burrell-
dc.language.isoen-
dc.publisherMARY ANN LIEBERT INC PUBL-
dc.rightsCopyright© Mary Ann Liebert, Inc. publishers. All rights reserved, USA and worldwide-
dc.subjectCell Line-
dc.subjectJurkat Cells-
dc.subjectHumans-
dc.subjectRetroviridae-
dc.subjectHIV-
dc.subjectRNA, Catalytic-
dc.subjectHIV Core Protein p24-
dc.subjectGene Products, tat-
dc.subjectRNA-
dc.subjectImmunoblotting-
dc.subjectTransduction, Genetic-
dc.subjectTransfection-
dc.subjectReverse Transcriptase Polymerase Chain Reaction-
dc.subjectGenetic Vectors-
dc.subjectModels, Biological-
dc.subjectTime Factors-
dc.subjecttat Gene Products, Human Immunodeficiency Virus-
dc.subjectGenetic Therapy-
dc.titleInterference between effector RNAs expressed from conventional dual-function anti-HIV retroviral vectors can be circumvented using dual-effector-cassette retroviral vectors-
dc.typeJournal article-
dc.identifier.doi10.1089/10430349950018896-
pubs.publication-statusPublished-
dc.identifier.orcidBurrell, C. [0000-0002-4020-349X]-
Appears in Collections:Aurora harvest 7
Microbiology and Immunology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.